Weetabix benefits from Covid breakfast boom to see sales rise

Weetabix

A resurgence of breakfasting during the pandemic helped Weetabix grow sales and profits last year, though pantry loading and reduced on-the-go consumption have hit volumes so far in 2021

Already have an account? Sign in here

Want access to this article?

Register for LIMITED access

REGISTER FOR FREE

Get PREMIUM access for £1 a week

SUBSCRIBE NOW